Progress made in understanding the building blocks of the human body has the potential to transform healthcare.
Using whole genome sequence analysis, micro biome mapping, advanced clinical imaging and innovative machine learning, we can for the first time have a complete picture of individual health.
HLI's goal is to extend and enhance the healthy, high-performance lifespan and change the face of ageing. For the first time, the power of human genomics, informatics, next generation DNA sequencing technologies, and stem cell advances are being harnessed in one company.
This will enable us to turn the lights on for medical professionals so they can truly tailer treatment to the individual.We are investing in businesses that have the power to transform our current understanding and change treatments and outcomes to enable people to enjoy longer healthier lives.
OxStem is positioned to transform the field of medical therapeutics for what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration, Diabetes and Oncology. The idea is straightforward: to use the Stem Cell and Medicinal Chemistry expertise at Oxford University to identify new classes of drugs that can re-program or stimulate existing endogenous cells, awakening previously defunct or dormant cellular processes.
Human Longevity, Inc. hires Cynthia Collins, Healthcare Industry Leader, as New Chief Executive Officer. Read the press release here.
OxStem Limited Establishes a Fourth Subsidiary Company: OxStem Cardio. View the full press release here.